46 research outputs found
Hospital admissions for severe infections in people with chronic kidney disease in relation to renal disease severity and diabetes status
Background: Immunosuppressive agents are being investigated for the treatment of
chronic kidney disease (CKD) but may increase risk of infection. This was a retrospective
observational study intended to evaluate the risk of hospitalized infection in
patients with CKD, by estimated glomerular filtration rate (eGFR) and proteinuria
status, aiming to identify the most appropriate disease stage for immunosuppressive
intervention.
Methods: Routine UK primary-care
and linked secondary-care
data were extracted
from the Clinical Practice Research Datalink. Patients with a record of CKD were
identified and grouped into type 2, type 1 and nondiabetes cohorts. Time-dependent,
Cox proportional hazard models were used to determine the likelihood of hospitalized
infection.
Results: We identified 97 839 patients with a record of CKD, of these 11 719 (12%)
had type 2 diabetes. In these latter patients, the adjusted hazard ratios (aHR) were
1.00 (95% CI: 0.80-1.25),
1.00, 1.03 (95% CI: 0.92-1.15),
1.36 (95% CI: 0.20-1.54),
1.82 (95% CI: 1.54-2.15)
and 2.41 (95% CI: 1.60-3.63)
at eGFR stages G1, G2 (reference),
G3a, G3b, G4 and G5, respectively; and 1.00, 1.45 (95% CI: 1.29-1.63)
and 1.91
(95% CI: 1.67-2.20)
at proteinuria stages A1 (reference), A2 and A3, respectively. All
aHRs (except G1 and G3a) were significant, with similar patterns observed within the
non-DM
and overall cohorts.
Conclusions: eGFR and degree of albuminuria were independent markers of hospitalized
infection in both patients with and without diabetes. The same patterns of
hazard ratios of eGFR and proteinuria were seen in CKD patients regardless of diabetes
status, with the risk of each outcome increasing with a decreasing eGFR and increasing
proteinuria. Infection risk increased significantly from eGFR stage G3b and
proteinuria stage A2 in type 2 diabetes. Treating type 2 DM patients with CKD at
eGFR stages G1-G3a
with immunosuppressive therapy may therefore provide a favourable
risk-benefit
ratio (G1-G3a
in type 2 diabetes; G1-G2
in nondiabetes and
overall cohorts) although the degree of proteinuria needs to be considered
Hospital admissions for severe infections in people with chronic kidney disease in relation to renal disease severity and diabetes status
Background: Immunosuppressive agents are being investigated for the treatment of
chronic kidney disease (CKD) but may increase risk of infection. This was a retrospective
observational study intended to evaluate the risk of hospitalized infection in
patients with CKD, by estimated glomerular filtration rate (eGFR) and proteinuria
status, aiming to identify the most appropriate disease stage for immunosuppressive
intervention.
Methods: Routine UK primary-care
and linked secondary-care
data were extracted
from the Clinical Practice Research Datalink. Patients with a record of CKD were
identified and grouped into type 2, type 1 and nondiabetes cohorts. Time-dependent,
Cox proportional hazard models were used to determine the likelihood of hospitalized
infection.
Results: We identified 97 839 patients with a record of CKD, of these 11 719 (12%)
had type 2 diabetes. In these latter patients, the adjusted hazard ratios (aHR) were
1.00 (95% CI: 0.80-1.25),
1.00, 1.03 (95% CI: 0.92-1.15),
1.36 (95% CI: 0.20-1.54),
1.82 (95% CI: 1.54-2.15)
and 2.41 (95% CI: 1.60-3.63)
at eGFR stages G1, G2 (reference),
G3a, G3b, G4 and G5, respectively; and 1.00, 1.45 (95% CI: 1.29-1.63)
and 1.91
(95% CI: 1.67-2.20)
at proteinuria stages A1 (reference), A2 and A3, respectively. All
aHRs (except G1 and G3a) were significant, with similar patterns observed within the
non-DM
and overall cohorts.
Conclusions: eGFR and degree of albuminuria were independent markers of hospitalized
infection in both patients with and without diabetes. The same patterns of
hazard ratios of eGFR and proteinuria were seen in CKD patients regardless of diabetes
status, with the risk of each outcome increasing with a decreasing eGFR and increasing
proteinuria. Infection risk increased significantly from eGFR stage G3b and
proteinuria stage A2 in type 2 diabetes. Treating type 2 DM patients with CKD at
eGFR stages G1-G3a
with immunosuppressive therapy may therefore provide a favourable
risk-benefit
ratio (G1-G3a
in type 2 diabetes; G1-G2
in nondiabetes and
overall cohorts) although the degree of proteinuria needs to be considered
Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial
Background:
Sodium–glucose co-transporter 2 inhibitors (SGLT2is) are part of the standard of care for patients with chronic kidney disease (CKD), both with and without type 2 diabetes. Endothelin A (ETA) receptor antagonists have also been shown to slow progression of CKD. Differing mechanisms of action of SGLT2 and ETA receptor antagonists may enhance efficacy. We outline a study to evaluate the effect of combination zibotentan/dapagliflozin versus dapagliflozin alone on albuminuria and estimated glomerular filtration rate (eGFR).
//
Methods:
We are conducting a double-blind, active-controlled, Phase 2b study to evaluate the efficacy and safety of ETA receptor antagonist zibotentan and SGLT2i dapagliflozin in a planned 415 adults with CKD (Zibotentan and Dapagliflozin for the Treatment of CKD; ZENITH-CKD). Participants are being randomized (1:2:2) to zibotentan 0.25 mg/dapagliflozin 10 mg once daily (QD), zibotentan 1.5 mg/dapagliflozin 10 mg QD and dapagliflozin 10 mg QD alone, for 12 weeks followed by a 2-week off-treatment wash-out period. The primary endpoint is the change in log-transformed urinary albumin-to-creatinine ratio (UACR) from baseline to Week 12. Other outcomes include change in blood pressure from baseline to Week 12 and change in eGFR the study. The incidence of adverse events will be monitored. Study protocol–defined events of special interest include changes in fluid-related measures (weight gain or B-type natriuretic peptide).
//
Results:
A total of 447 patients were randomized and received treatment in placebo/dapagliflozin (n = 177), zibotentan 0.25 mg/dapagliflozin (n = 91) and zibotentan 1.5 mg/dapagliflozin (n = 179). The mean age was 62.8 years, 30.9% were female and 68.2% were white. At baseline, the mean eGFR of the enrolled population was 46.7 mL/min/1.73 m2 and the geometric mean UACR was 538.3 mg/g.
//
Conclusion:
This study evaluates the UACR-lowering efficacy and safety of zibotentan with dapagliflozin as a potential new treatment for CKD. The study will provide information about an effective and safe zibotentan dose to be further investigated in a Phase 3 clinical outcome trial.
//
Clinical Trial Registration Number:
NCT0472483
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease
AIM: To assess the efficacy, safety and tolerability of cotadutide in patients with type 2 diabetes mellitus and chronic kidney disease. MATERIALS AND METHODS: In this phase 2a study (NCT03550378), patients with body mass index 25‐45 kg/m(2), estimated glomerular filtration rate 30‐59 ml/min/1.73 m(2) and type 2 diabetes [glycated haemoglobin 6.5‐10.5% (48‐91 mmol/mol)] controlled with insulin and/or oral therapy combination, were randomized 1:1 to once‐daily subcutaneous cotadutide (50‐300 μg) or placebo for 32 days. The primary endpoint was plasma glucose concentration assessed using a mixed‐meal tolerance test. RESULTS: Participants receiving cotadutide (n = 21) had significant reductions in the mixed‐meal tolerance test area under the glucose concentration‐time curve (–26.71% vs. +3.68%, p < .001), more time in target glucose range on continuous glucose monitoring (+14.79% vs. –21.23%, p = .001) and significant reductions in absolute bodyweight (–3.41 kg vs. –0.13 kg, p < .001) versus placebo (n = 20). In patients with baseline micro‐ or macroalbuminuria (n = 18), urinary albumin‐to‐creatinine ratios decreased by 51% at day 32 with cotadutide versus placebo (p = .0504). No statistically significant difference was observed in mean change in estimated glomerular filtration rate between treatments. Mild/moderate adverse events occurred in 71.4% of participants receiving cotadutide and 35.0% receiving placebo. CONCLUSIONS: We established the efficacy of cotadutide in this patient population, with significantly improved postprandial glucose control and reduced bodyweight versus placebo. Reductions in urinary albumin‐to‐creatinine ratios suggest potential benefits of cotadutide on kidney function, supporting further evaluation in larger, longer‐term clinical trials
Recommended from our members
Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr 1 ]apelin-13 in humans
Abstract: [Pyr1]apelin-13 is the predominant apelin peptide isoform in the human cardiovascular system and plasma. To date, few studies have investigated [Pyr1]apelin-13 metabolism in vivo in rats with no studies examining its stability in humans. We therefore aimed to develop an LC-MS/MS method for detection and quantification of intact [Pyr1]apelin-13 and have used this method to identify the metabolites generated in vivo in humans. [Pyr1]apelin-13 (135 nmol/min) was infused into six healthy human volunteers for 120 minutes and blood collected at time 0 and 120 minutes after infusion. Plasma was extracted in the presence of guanidine hydrochloride and analysed by LC-MS/MS. Here we report a highly sensitive, robust and reproducible method for quantification of intact [Pyr1]apelin-13 and its metabolites in human plasma. Using this method, we showed that the circulating concentration of intact peptide was 58.3 ± 10.5 ng/ml after 120 minutes infusion. We demonstrated for the first time that in humans, [Pyr1]apelin-13 was cleaved from both termini but the C-terminal was more susceptible to cleavage. Consequently, of the metabolites identified, [Pyr1]apelin-13(1–12), [Pyr1]apelin-13(1–10) and [Pyr1]apelin-13(1–6) were the most abundant. These data suggest that apelin peptides designed for use as cardiovascular therapeutics, should include modifications that minimise C-terminal cleavage
Recommended from our members
Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr 1 ]apelin-13 in humans
Abstract: [Pyr1]apelin-13 is the predominant apelin peptide isoform in the human cardiovascular system and plasma. To date, few studies have investigated [Pyr1]apelin-13 metabolism in vivo in rats with no studies examining its stability in humans. We therefore aimed to develop an LC-MS/MS method for detection and quantification of intact [Pyr1]apelin-13 and have used this method to identify the metabolites generated in vivo in humans. [Pyr1]apelin-13 (135 nmol/min) was infused into six healthy human volunteers for 120 minutes and blood collected at time 0 and 120 minutes after infusion. Plasma was extracted in the presence of guanidine hydrochloride and analysed by LC-MS/MS. Here we report a highly sensitive, robust and reproducible method for quantification of intact [Pyr1]apelin-13 and its metabolites in human plasma. Using this method, we showed that the circulating concentration of intact peptide was 58.3 ± 10.5 ng/ml after 120 minutes infusion. We demonstrated for the first time that in humans, [Pyr1]apelin-13 was cleaved from both termini but the C-terminal was more susceptible to cleavage. Consequently, of the metabolites identified, [Pyr1]apelin-13(1–12), [Pyr1]apelin-13(1–10) and [Pyr1]apelin-13(1–6) were the most abundant. These data suggest that apelin peptides designed for use as cardiovascular therapeutics, should include modifications that minimise C-terminal cleavage
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection:An Analysis of the DARE-19 Randomized Controlled Trial
Background and objectives: Patients who were hospitalized with coronavirus disease 2019 (COVID-19) infection are at high risk of AKI and KRT, especially in the presence of CKD. The Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial showed that in patients hospitalized with COVID-19, treatment with dapagliflozin versus placebo resulted in numerically fewer participants who experienced organ failure or death, although these differences were not statistically significant. We performed a secondary analysis of the DARE-19 trial to determine the efficacy and safety of dapagliflozin on kidney outcomes in the overall population and in prespecified subgroups of participants defined by baseline eGFR. Design, setting, participants, & measurements: The DARE-19 trial randomized 1250 patients who were hospitalized (231 [18%] had eGFR <60 ml/min per 1.73 m2) with COVID-19 and cardiometabolic risk factors to dapagliflozin or placebo. Dual primary outcomes (time to new or worsened organ dysfunction or death, and a hierarchical composite end point of recovery [change in clinical status by day 30]), and the key secondary kidney outcome (composite of AKI, KRT, or death), and safety were assessed in participants with baseline eGFR <60 and ≥60 ml/min per 1.73 m2. Results: The effect of dapagliflozin versus placebo on the primary prevention outcome (hazard ratio, 0.80; 95% confidence interval, 0.58 to 1.10), primary recovery outcome (win ratio, 1.09; 95% confidence interval, 0.97 to 1.22), and the composite kidney outcome (hazard ratio, 0.74; 95% confidence interval, 0.50 to 1.07) were consistent across eGFR subgroups (P for interaction: 0.98, 0.67, and 0.44, respectively). The effects of dapagliflozin on AKI were also similar in participants with eGFR <60 ml/min per 1.73 m2 (hazard ratio, 0.71; 95% confidence interval, 0.29 to 1.77) and ≥60 ml/min per 1.73 m2 (hazard ratio, 0.69; 95% confidence interval, 0.37 to 1.29). Dapagliflozin was well tolerated in participants with eGFR <60 and ≥60 ml/min per 1.73 m2. Conclusions: The effects of dapagliflozin on primary and secondary outcomes in hospitalized participants with COVID-19 were consistent in those with eGFR below/above 60 ml/min per 1.73 m2. Dapagliflozin was well tolerated and did not increase the risk of AKI in participants with eGFR below or above 60 ml/min per 1.73 m2
Recommended from our members
Glucagon and exenatide improve contractile recovery following ischaemia/reperfusion in the isolated perfused rat heart.
The inotropic effects of glucagon have been recognized for many years, but it has remained unclear whether glucagon signaling is beneficial to cardiac function. We evaluated the effects of glucagon alone and in combination with the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide in the isolated perfused rat heart. The isolated perfused rat heart was used to investigate the initial inotropic and chronotropic effects of glucagon and exenatide during aerobic perfusion, and recovery of contractile function following ischaemia/reperfusion. Glucagon, but not exenatide, elicited an acute chronotropic and inotropic response during aerobic perfusion of the rat heart. Compared with control, glucagon improved recovery of left ventricular developed pressure (LVDP) by 33% (p < 0.05) and rate-pressure product (RPP) by 66% (p < 0.001) following ischaemia/reperfusion and amplified the mild recovery enhancement elicited by exenatide in a dose-dependent manner. Glucagon shows inotropic properties in the isolated perfused rat heart and improves contractile recovery following ischaemia/reperfusion, both alone and when co-administered with a GLP-1 receptor agonist. Glucagon and exenatide, a GLP-1 receptor agonist, combine to stimulate greater recovery of postischaemic contractile function in the Langendorff heart. Glucagon was inotropic and chronotropic, yet this initial effect decreased over time and did not account for the increased contractility observed postischaemia/reperfusion